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Abstract
Background:  Double-blind randomised N-of-1 trials (N-of-1 trials) may help with decisions
concerning treatment when there is doubt regarding the effectiveness and suitability of medication
for individual patients. The patient is his or her own control, and receives the experimental and the
control treatment during several periods of time in random order. Reports of N-of-1 trials are still
relatively scarce, and the research methodology is not as firmly established as that of RCTs.
Recently, we have conducted two series of N-of-1 trials in general practice. Before, during, and
after data-collection, difficulties regarding outcome assessment, analysis of the results, the
withdrawal of patients, and the follow-up had to be dealt with. These difficulties are described and
our solutions are discussed.
Discussion: To prevent or anticipate difficulties in N-of-1 trials, we argue that that it is important
to individualise the outcome measures, and to carefully consider the objective, type of
randomisation and the analysis. It is recommended to use the same dosages and dosage forms that
the patient used before the trial, to start the trial with a run-in period, to formulate both general
and individualised decision rules regarding the efficacy of treatment, to adjust treatment policies
immediately after the trial, and to provide adequate instructions and support if treatment is
adjusted.
Summary: Because of the specific characteristics of N-of-1 trials it is difficult to formulate general
'how to do it' guidelines for designing N-of-1 trials. However, when the design of each N-of-1 trial
is tailored to the specific characteristics of each individual patient and the underlying medical
problem, most difficulties in N-of-1 trials can be prevented or overcome. In this way, N-of-1 trials
may be of help when deciding on drug treatment for individual patients.
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Background
In medical care, deciding on the optimal treatment for
individual patients is one of the main concerns of the phy-
sician. Scientific evidence, recommendations from guide-
lines, medical expertise, patient preferences, and personal
experiences all contribute to this decision process. Ran-
domised controlled trials (RCTs) are generally considered
to provide the strongest evidence for the efficacy of treat-
ment. However, RCTs are designed to estimate an average
treatment effect in a specific population [1]. In daily prac-
tice the physician has to determine the extent to which
this average effect will apply to an individual patient. For
instance, a patient who consults a physician may not be of
a similar age, may have additional co-morbidity and med-
ication, or may be interested in a different outcome com-
pared to the subjects studied in the related RCT.
Usually, when a physician doubts the applicability of
treatment recommendations (derived from RCTs) to a
specific patient, the trial and error method is used ('trial of
treatment') [2]. This means that a particular drug will be
prescribed, and, subsequently, continued if considered
effective, or changed if considered not beneficial. This
decision may be strongly influenced by expectations and
preferences of both patient and physician. N-of-1 trials
provide more objective evidence of individual benefit or
harm, while increasing the patient's involvement in the
management of his or her disease [3]. In contrast to RCTs,
N-of-1 trials do not assess what is best on average for a
whole population, but what is best for an individual
patient. The patient is his or her own control, and receives
the experimental and the control treatment during several
periods of time in random order. If possible, the patient,
the physician and the researcher are blinded for the
sequence of treatments [4]. Therefore, it is reasonable to
argue that N-of-1 trials may help physicians to provide
better care. However, it is impossible and undesirable to
tackle each treatment problem with an N-of-1 trial. Firstly,
there should be considerable doubt about the treatment
policy. Secondly, the disease or complaint has to be
chronic or recurrent, or drugs need to be prescribed for a
long period of time or for frequently repeated periods of
time. Finally, treatment effects should have a rapid onset
and stop acting soon after discontinuation [4].
Reports of N-of-1 trials in general practice are still rela-
tively scarce, and the research methodology is not as
firmly established as that of RCTs. Recently, we have con-
ducted two series of N-of-1 trials (Table 1), one in patients
with osteoarthritis of the hip or knee (series A), and one
in long-term users of temazepam (series B) [5,6]. Before,
during, and after data-collection, a number of difficulties
had to be dealt with. The aim of this paper is to describe
the difficulties we encountered during these series and to
discuss our solutions. Successively, difficulties with regard
to the outcome assessment, the analysis of the results, the
withdrawal of patients, and follow-up will be discussed.
We used our own experiences, and searched the literature
(Medline 1966 until now, using the search term "N-of-1
trial") to incorporate suggestions made by other research-
ers regarding the methodology of N-of-1 trials.
Discussion
Outcome assessment
Problem: which outcome measures should be used?
In a series of N-of-1 trials it seems logical to use the same
outcome measures for all patients within one series (as in
an RCT). However, since every patient is analysed sepa-
rately in N-of-1 trials, the outcome measures do not have
to be the same for all patients in a series. It is more impor-
tant that the outcome measures are relevant for each indi-
vidual patient [7]. On the other hand, in a series of N-of-
1 trials, it is of interest to demonstrate variation (hetero-
geneity) in the results across patients. Therefore, the out-
come measures for the different patients should be
comparable.
Measures taken: outcome measures were individualised
Using the methods proposed by Guyatt et al. [4,8] and
Beurskens et al. [9], all patients from series A were asked
before the start of their trial to identify their most impor-
tant problems regarding osteoarthritis. Every day each
patient scored the severity of these problems (four to eight
items) on a 7-point ordinal scale ranging between 0 = no
problem at all and 6 = very severe problem. Examples of
such problems were: pain in the knee when going up and
down stairs, pain in the knee when lifting shopping bags,
stiffness of the knee when getting out of bed. As all items
were scored on a similar scale (7-point ordinal scale), dif-
ferences in the effect of the treatment on the severity of the
individual complaints could be compared across patients.
Outcome measures were also individualised for series B,
in which the patients could select their main problem
among a set of questions regarding quantity or quality of
sleep.
Results of measures
Because we used individualised outcome measures, we
were able to formulate treatment recommendations based
on the results of patient-specific outcomes. In addition,
the patients found it easy to answer questions reflecting
their main problems, and completion rates were high. For
all patients who finished their trial the completion rate for
the main problems was at least 99% in series A, and 82%
to 100% in series B. Furthermore, using the same 7-point
scale for each problem enabled us to study heterogeneity
among patient outcomes. The results ranged from no dif-
ference to large differences in favour of non-steroidal anti-
inflammatory drugs (NSAIDs) compared to paracetamol
in series A, and similarly in series B from no difference toBMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
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large differences in favour of temazepam compared to pla-
cebo or a lower dosage of temazepam.
Recommendations
Identification of the main complaint in each patient, yet
using the same scale to assess the outcomes for all patients
in a series, enables the investigator to present each patient
with individualised results and treatment recommenda-
tions and, simultaneously, to make comparisons of the
results across patients. This approach has been used
sucessfully in other N-of-1 trials, investigating the effec-
tiveness of theophylline for irreversible chronic airflow
limitation [10] or the efficacy of quinine in leg cramps
[11]. Alternatively, patients participating in N-of-1 trials
have been asked to give a global assessment of the effec-
tiveness of the medication, and indicate a preference after
each treatment pair [12]. Such an assessment is patient
centred, and can also take into consideration both benefi-
cial and adverse effects of treatment.
Analysis of results
Problem: how should the outcomes of the N-of-1 trials be analysed?
In both our series, the N-of-1 trials consisted of five pairs
of treatment periods. Each patient received during one
period of each pair the active treatment (treatment X), and
during the other period the control treatment or placebo
(treatment Y). For each patient, the sequence of treat-
ments (XY or YX) was randomised within each pair of
treatment periods (Figure 1).
Since N-of-1 trials are meant to evaluate individual treat-
ment effects (and not to estimate the average effect in a
larger population), results are analysed for each patient
separately. The possibilities of statistical testing for signif-
icance, however, are limited, but in some studies the
paired t-test has been used [8,13,14]. The disadvantage of
this test is that it assumes a normal distribution of the
data, and independence of data from treatment periods.
The problem of autocorrelation (i.e. the data are not inde-
pendent) can be solved by using the average of the data in
each treatment period instead of all individual data [4],
while non-parametric tests can be applied to tackle viola-
tions of the normality assumption. Furthermore, time-
series analysis can sometimes be used. In time-series anal-
ysis, data over time are compared for separate treatment
periods. Time-series analysis is appropriate when there is
serial dependency in the data (i.e. successively measured
data are significantly correlated). One limitation is that
time-series analysis requires a large number of observa-
tions in each treatment period. As N-of-1 trials are often
designed with relatively short treatment periods, time-
series analysis is not really appropriate [15].
Also, non-parametric tests, such as the sign test or the ran-
domisation test can be used. These tests do not require a
normal distribution of the data. The disadvantage of the
sign test is that it lacks power. At least five pairs of treat-
ment periods are necessary before the significance level of
0.05 can be reached (1/25) [4], irrespective of the magni-
tude of difference between the treatments. This is the rea-
son why we used five pairs of treatment periods in both
our series. With the randomisation test, the power can be
increased by using less restricted randomisation schedules
[16,17]. For example, if 5 of the 10 periods in our N-of-1
series had been randomly assigned (without restrictions)
to treatment X and the other five to treatment Y, the small-
est possible p-value would have been 1/252 = 0.004 (=1/
number of randomisation possibilities, in this case 1/
Table 1: Details of two series of N-of-1 trials conducted by our research group
Series A [3] Series B [4]
Setting General practice General practice
Subjects Patients who had been taking NSAIDs regularly in the 
treatment of pain and disability related to osteoarthritis 
of the hip or knee.
Long-term users of temazepam (10 or 20 mg) for sleep 
disturbances.
Objective 1) Is paracetamol as effective as NSAIDs?
2) Is medication-use influenced by presenting the 
personal results to each individual patient?
1) Is placebo as effective as temazepam (10 or 20 mg), or, 
in some patients, is 10 mg temazepam as effective as 20 
mg temazepam?
2) Is medication-use influenced by presenting the 
personal results to each individual patient?
Primary outcome measures 1) individual main complaints
2) intensity of pain
1) individual main complaint
2) time to fall asleep
Treatment pairs 2 weeks of paracetamol and 2 weeks of NSAIDs 1 week of placebo and 1 week of 10 mg temazepam, or
1 week of placebo and 1 week of 20 mg temazepam, or
1 week of 10 mg temazepam and 1 week of 20 mg 
temazapam
Total trial period 20 weeks (5 pairs of treatment periods) 10 weeks (5 pairs of treatment periods)
Sequence of treatments Randomisation within each treatment pair Randomisation within each treatment pair
Blinding The patient, the investigator and the GP were blinded for 
the sequence of treatments.
The patient, the investigator and the GP were blinded for 
the sequence of treatments.BMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
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[10!/5!5!] = 1/252). In case of four periods of treatment X
and four periods of treatment Y, this would still be 0.014
(1/[8!/4!4!]). However, restrictions are often necessary to
ensure, for example, that the active treatment periods are
not all concentrated at the end of the trial, while it could
be possible that the patient improves spontaneously [17].
In our series, however, we did not investigate whether one
treatment was better than the other, but whether one
treatment was equally effective as the other. In other
words, the trials we conducted were equivalence trials,
rather than superiority trials, which meant that conven-
tional significance testing could not be used for analysis
[18-20]. Since 'no difference' between two different treat-
ments cannot be proven, an equivalence range is defined
before the start of the trial, i.e. a range of differences
between treatments that are considered to be of no clinical
importance. If the confidence interval of the difference
between treatments lies entirely within this equivalence
range, equivalence may be concluded with only a small
probability of error [18]. To test equivalence a large
number of data are required: the smaller the equivalence
range, the more data are needed [18,21,22]. As stated
above, the number of observations are often very small in
N-of-1 trials, and equivalence testing may not be feasible.
Measures taken: computation of median differences in outcomes, 
and definition of cut-off points
For both series, we decided to define (a priori) cut-off
points for a minimal important difference on each pri-
mary outcome. In this way we could distinguish between
equivalence of effects, small, or large differences in the
effectiveness of medication. Given the non-normal distri-
bution of our data, we calculated differences in median
scores between the two treatments for each outcome
measure. For example, for series B, a median difference in
the time to fall asleep of at least 30 minutes in favour of
temazepam was considered to be a large effect, 5 to 30
minutes a small effect, and <5 minutes no effect of
temazepam.
Recommendations
When setting up an N-of-1 trial the investigator should
carefully consider the objective of the trial. If the aim is to
evaluate whether another type of medication is more
effective than current treatment, the trial can be designed
as a superiority trial, and conventional tests of significance
may be applied during the analysis. If, however, the aim is
to confirm the equivalence of two (or more) treatments
(which is the case in all efforts to reduce or stop medica-
tion), the N-of-1 trial is an equivalence trial, and requires
a different method of analysis, with a strong emphasis on
the definition of a minimal important difference, and suf-
ficient observations to enable equivalence testing.
Several other researchers have formulated cut-off points
or defined responders and non-responders according to
the number of pairs in which a clear difference between
treatments was seen [23-26]. Patient preferences can be
used to determine the outcome of an N-of-trial, with
superiority of a drug established if – in a pre-determined
proportion of treatment pairs – the patients favours one
treatment over the other. In some studies researchers have
used this method to allow for a variable number of treat-
ment pairs among patients, with a trial being stopped
early in case of strong preferences by either physican or
patient [10].
More recently, hierarchical Bayesian methods have been
proposed for the statistical analysis of series of N-of-1 tri-
als [27-29]. The objective of this approach is to use indi-
vidual patient assessments to obtain an overall
population estimate of treatment effectiveness that takes
into account both the magnitude of the effect, as well as
Example of randomisation schedule for one patient receiving 5 pairs of treatment, each consisting of one week of treatment X  and one week of treatment Y Figure 1
Example of randomisation schedule for one patient receiving 5 pairs of treatment, each consisting of one week of treatment X 
and one week of treatment Y.
    Pair 1 Pair 2    Pair 3      Pair 4        Pair 5 
weeks      t =  0   1 2     3    4  5 6  7 8     9  10 
Ƒ Treatment X
Ŷ Treatment YBMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
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the heterogeneity in individual treatment responses [28].
Bayesian methods have the advantage of allowing for the
introduction of co-variates in the model, and for embod-
ying prior information [27]. Therefore, information
acquired from previous patients will aid the interpretation
of subsequent N-of-1 trial results [27,28]. As the under-
standing of treatment responses and precision of esti-
mates improve over time, N-of-1 trials may need less
cross-overs (treatment pairs) to obtain the same amount
of information, or even become unnecessary [28].
Withdrawal
Problem: withdrawal from the trials
Six of the 13 patients (46%) in series A, and three of the
15 patients (20%) in series B, did not complete their trial
period. The reasons for withdrawal (as given by the
patients) are summarised in Table 2.
Perceived lack of efficacy
Four patients in series A did not finish their trial because
of perceived lack of efficacy. Three of these four patients
received dosages of NSAIDs during their trial that were
lower than they had taken before the trial. The other
patient had taken additional paracetamol/codeine before
the start of her trial, but was asked not do so during the
trial. These findings suggest that the withdrawal of these
patients was due to subtherapeutic dosages of medication
during their trials. In series B, two patients did not com-
plete their trial because of perceived lack of efficacy. The
participants were aware that they would receive placebo
or a lower dosage of temazepam half of the time, and may
have expected poor results. These expectations may have
contributed to a perceived lack of efficacy.
Perceived side effects
In both series one patient withdrew because of perceived
side effects. Before the start of the trial the patient who
withdrew from series A was used to taking diclofenac tab-
lets. To ensure blinding during the trial she received iden-
tical capsules containing either diclofenac and placebo, or
paracetamol. As the participant reported abdominal com-
plaints during both periods it is possible that these symp-
toms were caused by the gelatine capsules. Similarly, a
patient in series B received medication in a different dos-
age form (tablets instead of temazepam capsules). This
patient reported nausea, and withdrew after a few days.
The reports of nausea and abdominal complaints may
also have been the result of pure coincidence, or perhaps,
be related to concerns regarding the effects of taking med-
ication in another form.
Duration of the trial
In series A the duration of the trial was 20 weeks, and in
series B it was 10 weeks, which made it easier for the
patients in series B to complete their trial. In series A, one
patient withdrew because the study took too long and
because of coexisting symptoms (back pain). None of the
patients in series B withdrew because the trial took too
long.
Recommendations
A number of measures can be taken to prevent withdrawal
due to subtherapeutic dosages or (perceived) side effects.
Firstly, the drug can be prescribed in the same dosage and
form as the patient is used to. Secondly, the trial can be
started with a run-in period, during which the patient
receives the drug in the dosage and form in which it will
be prescribed during the trial. In this way, the patient can
withdraw from the trial at an early stage, or the medica-
tion can be adjusted before the data-collection actually
starts. Finally, if blinding is difficult because of insur-
mountable differences in the form, size, colour, smell or
taste of the medication, the double-dummy design can be
used. In a double-dummy design the patient receives
active treatment X and placebo treatment Y during one
period, and placebo treatment X and active treatment Y
during the other. However, this will increase the number
of tablets that need to be taken, possibly leading to non-
compliance or withdrawal [23].
An alternative method to prevent withdrawal due to
expectations of poor results is to keep the patients com-
pletely unaware of the dosages. However, this may not
receive ethical approval. Furthermore, to prevent with-
drawal due to the length of the trial, treatment periods can
be kept as short as possible. Such a decision will affect the
power of the trial. In a commentary on an N-of-1 trial in
a pregnant woman with nausea and morning sickness
[30-32] Campbell discussed the length of treatment peri-
ods [33]. While the total trial period should not be too
long [34] the separate treatment periods should be long
Table 2: Reasons for withdrawal from the trials
Reasons for withdrawal No. of patients in series A No. of patients in series B
Perceived lack of efficacy 4 2
Perceived side effects 1 1
Duration of trial period too long 1 -
Series A: NSAIDs or paracetamol for osteoarthritis
Series B: reduction of temazepam for sleep disturbancesBMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
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enough to achieve and detect a clinically important treat-
ment effect [31].
Withdrawal rate in series of N-of-1 trials conducted in pri-
mary care range between 12 and 40%, with similar rea-
sons for discontinuing participation [2,11-13,24-26,29].
Nikles et al. proposed that withdrawal rates can be
thought of as a general measure of compliance (or adher-
ence), which is often not as good as clinicians believe.
Non-adherence rates of around 50% have been reported
for several chronic conditions [2].
Follow-up
Problem: reverting to the same medication as before the N-of-1 trial
After the completion of a trial we visited participants at
home to discuss their results. Subsequently, patients were
asked about their intentions regarding future medication
intake for osteoarthritis (series A) or sleep disturbances
(series B), and general practitioners (GPs) were informed
about these intentions. However, three months after the
completion of series A, four of the six patients who
intended to switch to paracetamol were taking NSAIDs for
osteoarthritis, and one patient was taking both paraceta-
mol and NSAIDs. In series B, two of the nine patients who
intended to reduce or stop their temazepam intake had
reverted to their previous dosage. The reasons for reverting
to the same medication are summarised in Table 3.
Patients were not sufficiently instructed, coached and/or monitored
One patient from series A indicated that she had reverted
to taking NSAIDs because the paracetamol was not suffi-
ciently effective. However, instead of taking 1000 mg
paracetamol three times a day, the patient had been taking
500 mg twice a day. After solving this misunderstanding,
the patient agreed to start taking paracetamol again.
Another patient considered it a waste to throw away the
NSAIDs and wanted to finish her supply before starting
the paracetamol treatment. In one patient from series B
the dosage of temazepam had not (yet) been reduced.
Since the end of the trial, the patient had not seen the GP
and neither the patient nor the GP had taken any action
to adjust the treatment policy. Obviously, these three
patients were not sufficiently instructed by the researcher
or sufficiently coached and monitored by the GP.
Motivation to adjust treatment
In one patient from series B temazepam had little effect on
the quality or quantity of sleep, but the patient saw no dis-
advantage in taking temazepam and decided to take it just
as frequently as before the trial.
Recommendations
Only few reports on N-of-1 trials have discussed the long-
term effects of participating in an N-of-1 trial [10-12].
Both Woodfied et al. [11] and Mahon et al. [10] com-
mented on the fact that a considerable number of partici-
pants decide to resume or continue the use of active
medication, despite results of the trial indicating a lack of
effectiveness. Some of these decisions were explained by
the fact that participants returned to their own non-study
physician after completion of the trial. To prevent patients
from reverting to previous treatment, a number of meas-
ures can be taken: (1) before the start of the trial the
patients should be well informed about the objectives
and, especially, the possible consequences of the trial, (2)
the GP (together with the researcher) should discuss the
results with the patient and adjust (if appropriate) the
treatment policy immediately, (3) the patients should be
well instructed and encouraged to follow treatment rec-
ommendations, and (4) monitoring may be needed for
some time. Furthermore, before the start of a trial, the
patient's reasons for participation should be investigated.
Patients should be willing to question their current treat-
ment, and adjust their treatment, if necessary [35]. We
suggest to define a minimal important difference for each
patient before the start of the trial. This will establish indi-
vidually relevant decision rules with clear agreements
regarding the interpretation of results and decisions
regarding the future treatment policy.
Summary
Given the importance of adjusting the design of an N-of-
1 trial to the specific characteristics of each individual
patient, it is difficult to formulate general 'how to do it'
Table 3: Follow-up: Reasons for reverting to the same medication as before the N-of-1 trial
Reasons for reverting in series A
• Perceived lack of efficacy of paracetamol
• Deterioration of osteoarthritis
• Misunderstanding regarding paracetamol dosage
• Preference of small tablets (diclofenac) over larger ones (paracetamol)
• Patient found it a waste to throw away the NSAIDs she still had in her possession
Reasons for reverting in series B
• Dosage of temazepam had not been adjusted after the N-of-1 trials
• Patient sees no disadvantages in taking temazepam
Series A: NSAIDs or paracetamol for osteoarthritis
Series B: reduction of temazepam for sleep disturbancesBMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
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guidelines for N-of-1 trials. However, when the design of
each N-of-1 trial is tailored to the specific characteristics of
each individual patient and the underlying medical prob-
lem, most difficulties in N-of-1 trials may be prevented or
overcome. In our opinion, it is important to carefully con-
sider the objective of the trial, and, with that, the ran-
domisation schedule and the type of analysis.
Furthermore, it is important to individualise outcome
measures, so that they are relevant for each patient. We
recommend that dosage and form of medication is the
same as before the trial, and that the trial starts with a run-
in period. General decision rules regarding the efficacy of
treatment may help to demonstrate variation across
patients, but we also recommend to formulate individual-
ised decision rules for the future use of medication before
the start of a trial. Finally, patients need to be provided
with adequate instructions and support after adjustments
of treatment.
Usefulness and implementation of N-of-1 trials
The value of N-of-1 trials for making decisions in individ-
ual patients, through bridging the gap between research
and practice, allowing for an individual approach, and
incorporating patient values, has been well-accepted [36].
Results of randomised N-of-1 trials have even been placed
in the top of the hierarchy of evidence [37]. However, few
studies have evaluated their usefulness in clinical practice,
or assessed potential barriers to more widespread imple-
mentation of this approach. Wide experience has been
gained in Australia, where a national N-of-1 service has
been implemented. The service has been promoted
through clinical meetings, newsletters, websites, and the
media [26]. Several large series of N-of-1 trials have been
undertaken [26,29,38]. Qualitative research showed that
patients were generally very satisfied with the N-of-1 trial
process. Their participation led to increased awareness
and understanding of their condition, and its manage-
ment, resulting in a sense of empowerment and control
[2]. The effort of setting up an N-of-1 trial in primary care,
however, is substantial [3], especially outside the setting
of an N-of-1 trial service. It includes the costs of paper-
work and consent forms, arranging identical placebo's
from a pharmacy, designing and printing diaries, statisti-
cal analysis, and time spent informing and instructing
patients.
The ultimate test of the usefulness of N-of-1 trials in clin-
ical practice is to compare the outcome of N-of-1 trials in
terms of costs and patient benefits to usual care in a ran-
domised design. Two such randomised trials have been
undertaken. Mahon et al. [10] evaluated whether patients
with irreversible chronic airflow limitation who were pre-
scribed theophylline guided by N-of-1 trials had better
outcomes than patients treated according to standard
practice. The use of N-of-1 trials did not yield important
advantages over standard practice. Pope et al. compared
the efficacy and cost-effectiveness of placebo-controlled
N-of-1 trials with diclofenac/misoprostol to standard care
among patients with osteoarthritis who were uncertain
that NSAIDs would be helpful [12]. The N-of-1 trials
yielded slightly better improvements than standard care,
but the difference was not statistically significant. Both tri-
als showed that the costs of N-of-1 trials were considera-
bly higher than those of standard care, due to the costs
associated with the production of placebo's, and time
spent by nurses, physicians, and patients. These were the
first trials that formally evaluated the cost-effectiveness of
implementing N-of-1 trials in clinical practice. The
number of patients involved was rather small, and follow-
up was limited to six or 12 months. Additional research
among patients with different types of medical problems
is needed to firmly establish the value and need of the N-
of-1 approach in primary care.
Competing interests
The author(s) declare that they have no competing inter-
ests.
Authors' contributions
All four authors discussed with eachother the themes of
this manuscript and made substantial contibutions to the
design of the manuscript. AW and DvdW drafted the man-
uscript and the other authors revised it critically. All four
authors have read and approved the final version of the
paper.
Acknowledgements
The work was performed at the EMGO Institute, Department of General 
Practice, VU University Medical Center, Amsterdam, The Netherlands. The 
study was supported unconditionally by Leo Pharma, The Netherlands.
References
1. Altman DG: Practical statistics for medical research London: Chapman &
Hall; 1991:1-9. 
2. Nikles CJ, Clavarino AM, Del Mar CB: sing n-of-1 trials as a clini-
cal tool to improve prescribing.  Br J Gen Pract 2005, 55:175-80.
3. Madhok V, Fahey T: N-of-1 trials: an opportunity to tailor treat-
ment in individual patients.  Br J Gen Pract 2005, 55:172.
4. Guyatt G, Sackett D, Adachi J, Roberts R, Chong J, Rosenbloom D,
Keller J: A clinician's guide for conducting randomized trials
in individual patients.  CMAJ 1988, 139:497-503.
5. Wegman ACM, Van der Windt DAWM, De Haan M, Devillé WLJM,
Chin A, Fo CT, De Vries ThPGM: Switching from NSAIDs to
paracetamol: a series of n of 1 trials for individual patients
with osteoarthritis.  Ann Rheum Dis 2003, 62:1156-1161.
6. Wegman ACM, Van der Windt DAWM, Bongers M, Twisk JWR, Stal-
man WAB, De Vries ThPGM: Efficacy of temazepam in frequent
users: a series of N-of-1 trials.  Fam Pract 2005, 22:152-159.
7. Guyatt G, Sackett D, Taylor DW, Chong J, Roberts R, Pugsley S:
Determing optimal therapy – randomized trials in individual
patients.  N Engl J Med 1986, 314:889-892.
8. Guyatt GH, Keller JL, Jaeschke R, Rosenbloom D, Adachi JD, New-
house MT: The n-of-1 randomized controlled trial: clinical
usefulness, our three-year experience.  Ann Intern Med 1990,
112:293-299.
9. Beurskens AJ, De Vet HC, Koke AJ, Lindeman E, Van der Heijden GJ,
Regtop W, Knipschild PG: A patient-specific approach for meas-Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Family Practice 2006, 7:54 http://www.biomedcentral.com/1471-2296/7/54
Page 8 of 8
(page number not for citation purposes)
uring functional status in low back pain.  J Manipulative Physiol
Ther 1999, 22:144-148.
10. Mahon JL, Laupacis A, Hodder RV, McKim DA, Paterson NA, Wood
TE, Donner A: Theophylline for irreversible chronic airflow
limitation: a randomized study comparing n of 1 trials to
standard practice.  Chest 1999, 115:38-48.
11. Woodfield R, Goodyear-Smith F, Arroll B: N-of-1 trials of quinine
efficacy in skeletal muscle cramps of the leg.  Br J Gen Pract
2005, 55:181-5.
12. Pope JE, Prashker M, Anderson J: The efficacy and cost effective-
ness of N of 1 studies with diclofenac compared to standard
treatment with nonsteroidal antiinflammatory drugs in oste-
oarthritis.  J Rheumatol 2004, 31:140-9.
13. March L, Irwig L, Schwarz J, Simpson J, Chock C, Brooks P: N of 1
trials comparing a non-steroidal anti-inflammatory drug
with paracetamol in osteoarthritis.  BMJ 1994, 309:1041-1045.
discussion 1045–1046
14. Haas DC, Sheehe PR: Dextroamphetamine pilot crossover tri-
als and n of 1 trials in patients with chronic tension-type and
migraine headache.  Headache 2004, 44:1029-37.
15. Kazdin AE: Statistical analyses for single-case experimental
designs.  In Single case experimental designs – strategies for studying
behavior change 2nd edition. Edited by: Barlow DH, Hersen M. New
York: Pergamon Press; 1984:285-324. 
16. Onghena P, Edington ES: Randomization tests for restricted
alternating treatments designs.  Behav Res Ther 1994,
32:783-786.
17. Spiegelhalter DJ: Statistical issues in studies of individual
response.  Scand J Gastroenterol Suppl 1988, 147:40-45.
18. Jones B, Jarvis P, Lewis JA, Ebbutt AF: Trials to assess equivalence:
the importance of rigorous methods.  BMJ 1996, 313:36-39.
19. Senn S, Bakshi R, Ezzet N: Caution in interpretation needed.
[letter].  BMJ 1995, 310:667.
20. Altman DG: Absence of evidence is not evidence of absence.
BMJ 1995, 311:485.
21. Ebutt AF, Frith L: Practical issues in equivalence trials.  Stat Med
1998, 17:1691-1701.
22. Hermens ML, Van Hout HP, Terluin B, Ader HJ, De Haan M: The
importance of equivalence trials in showing the usefulness
oftreatments. [In Dutch: Het belang van equivalentieonder-
zoek om de waarde van behandelingen aan te tonen].  Ned
Tijdschr Geneeskd 2003, 147:2162-2166.
23. Nikles CJ, Glasziou PP, Del Mar CB, Duggan CM, Clavarino A, Yelland
MJ: Preliminary experiences with a single-patient trials serv-
ice in general practice.  Med J Aust 2000, 173:100-103.
24. Yelland MJ, Nikles CJ, McNairn N, Del Mar CB, Schluter PJ, Brown
RM: Celecoxib compared with sustained-release paraceta-
mol for osteoarthritis: a series of n-of-1 trials.  Rheumatology
(Oxford)  in press. 2006, Jun 15
25. Kent MA, Camfield CS, Camfield PR: Double-blind methylpheni-
date trials: practical, useful, and highly endorsed by families.
Arch Pediatr Adolesc Med 1999, 153:1292-96.
26. Nikles CJ, Mitchell GK, Del Mar CB, Clavarino A, McNairn N: An n-
of-1 trial service in clinical practice: testing the effectiveness
of stimulants for attention-deficit/hyperactivity disorder.
Pediatrics 2006, 117:2040-6.
27. Schluter PJ, Ware RS: Single patient (n-of-1) trials with binary
treatment preference.  Stat Med 2005, 24:2625-36.
28. Zucker DR, Schmid CH, McIntosh MW, D'Agostino RB, Selker HP,
Lau J: Combining single patient (N-of-1) trials to estimate
population treatment effects and to evaluate individual
patient responses to treatment.  J Clin Epidemiol 1997, 50:401-10.
29. Coxeter PD, Schluter PJ, Eastwood HL, Nikles CJ, Glasziou PP: Vale-
rian does not appear to reduce symptoms for patients with
chronic insomnia in general practice using a series of ran-
domised n-of-1 trials.  Complement Ther Med 2003, 11:215-22.
30. Harker N, Montgomery A, Fahey T: Treating of nausea and vom-
iting during pregnancy: case presentation.  BMJ 2004, 328:276.
31. Harker N, Montgomery A, Fahey T: Treating nausea and vomit-
ing during pregnancy: case progression.  BMJ 2004, 328:337.
32. Harker N, Montgomery A, Fahey T: Treating of nausea and vom-
iting during pregnancy: case outcome.  BMJ 2004, 328:503.
33. Campbell MJ: Commentary: statistical aspects.  BMJ 2004,
328:506.
34. Johannessen T: Controlled trials in single subjects: Value in
clinical medicine.  BMJ 1991, 303:173-174.
35. Jull A, Bennett D: Do n-of-1 trials really tailor treatment?  Lancet
2005, 365:1992-4.
36. Johnston BC, Mills E: N-of-1 randomized controlled trials: an
opportunity for complementary and alternative medicine
evaluation.  J Altern Complement Med 2004, 10:979-84.
37. Guyatt G, Haynes B, Jaeschke R, Cook D, Greenhalgh T, Mead M,
Green L, Naylor CD, Wilson M, McAlister F, Richardson WS: Intro-
duction: the philosophy of evidence-based medicine.  In Users'
guides to the medical literature Edited by: Guyatt G, Rennie D. Chicago:
Americal Medical Association Press; 2002:3-11. 
38. Nikles CJ, Yelland M, Glasziou PP, Del Mar C: Do individualized
medication effectiveness tests (n-of-1 trials) change clinical
decisions about which drugs to use for osteoarthritis and
chronic pain.  Am J Ther 2005, 12:92-7.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2296/7/54/prepub